Key result
Different patterns of renin-angiotensin system blocker use in advanced chronic kidney disease showed no significant difference in the risk for kidney failure or mortality.
Why the study?
Does continuing renin-angiotensin system blockade reduce mortality and kidney failure in patients with advanced chronic kidney disease?
Does continuing renin-angiotensin system blockade reduce mortality and kidney failure in patients with advanced chronic kidney disease?
No takes yet. Share an insight, caveat, or question.
While retrospective data suggest RAS inhibition in advanced CKD is safe, its benefit on hard endpoints remains uncertain, necessitating randomized controlled trials.
Michel Burnier (2020) conducted an editorial in Advanced chronic kidney disease (n=678). Renin-angiotensin system (RAS) blockers vs. Always users was evaluated on Kidney failure or mortality. Different patterns of renin-angiotensin system blocker use in advanced chronic kidney disease showed no significant difference in the risk for kidney failure or mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: